Sawai Group Holdings Co Ltd
TSE:4887

Watchlist Manager
Sawai Group Holdings Co Ltd Logo
Sawai Group Holdings Co Ltd
TSE:4887
Watchlist
Price: 2 200.5 JPY 0.92% Market Closed
Market Cap: 289.3B JPY
Have any thoughts about
Sawai Group Holdings Co Ltd?
Write Note

Gross Margin
Sawai Group Holdings Co Ltd

30.7%
Current
32%
Average
48.4%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
30.7%
=
Gross Profit
54.5B
/
Revenue
177.3B

Gross Margin Across Competitors

Country JP
Market Cap 272.8B JPY
Gross Margin
31%
Country JP
Market Cap 776 550.9T JPY
Gross Margin
-3%
Country US
Market Cap 755.8B USD
Gross Margin
81%
Country UK
Market Cap 440.4B GBP
Gross Margin
56%
Country DK
Market Cap 2.7T DKK
Gross Margin
85%
Country US
Market Cap 351.1B USD
Gross Margin
69%
Country US
Market Cap 251.8B USD
Gross Margin
77%
Country CH
Market Cap 200.1B CHF
Gross Margin
73%
Country UK
Market Cap 161.8B GBP
Gross Margin
82%
Country CH
Market Cap 171.5B CHF
Gross Margin
75%
Country US
Market Cap 151.5B USD
Gross Margin
71%
No Stocks Found

Sawai Group Holdings Co Ltd
Glance View

Market Cap
272.8B JPY
Industry
Pharmaceuticals

Sawai Group Holdings Co., Ltd. stands as a prominent figure in the pharmaceutical landscape of Japan and beyond, rooted in a steadfast commitment to produce affordable generic medicines. Originating from humble beginnings in 1929, Sawai has evolved into a formidable player in the industry, underpinned by a strategy that blends innovation with an intricate understanding of healthcare needs. Known for its sharp focus on generic pharmaceutical products, the company has carved a niche by prioritizing the development and manufacture of high-quality, cost-efficient medications. This strategic orientation not only aligns with global healthcare trends but also meets the burgeoning demands of an aging population, both domestically and internationally. Central to Sawai's business model is their vertically integrated operation, covering everything from research and development to manufacturing and distribution. This comprehensive approach allows Sawai to maintain strict control over product quality while maximizing operational efficiency. Revenue flows from its diverse product portfolio, which includes a vast array of therapeutic areas such as cardiovascular, digestive, and central nervous system drugs. Moreover, Sawai's expansion into international markets, particularly in the United States through its subsidiary Upsher-Smith Laboratories, broadens its revenue base. By leveraging strategic acquisitions and partnerships, the company continues to fortify its presence on the global stage, all while steadfastly delivering on its promise of making healthcare accessible and affordable.

Intrinsic Value
2 890.58 JPY
Undervaluation 24%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
30.7%
=
Gross Profit
54.5B
/
Revenue
177.3B
What is the Gross Margin of Sawai Group Holdings Co Ltd?

Based on Sawai Group Holdings Co Ltd's most recent financial statements, the company has Gross Margin of 30.7%.